Free Trial
NASDAQ:RNTX

Rein Therapeutics (RNTX) Stock Price, News & Analysis

Rein Therapeutics logo
$1.82 +0.18 (+10.98%)
As of 05/2/2025 03:59 PM Eastern

About Rein Therapeutics Stock (NASDAQ:RNTX)

Key Stats

Today's Range
$1.53
$1.82
50-Day Range
$1.39
$2.20
52-Week Range
$1.35
$4.40
Volume
24,770 shs
Average Volume
53,292 shs
Market Capitalization
$40.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Receive RNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rein Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RNTX Stock News Headlines

The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
Q2 EPS Estimate for Rein Therapeutics Increased by Analyst
See More Headlines

RNTX Stock Analysis - Frequently Asked Questions

Rein Therapeutics' stock was trading at $2.05 on January 1st, 2025. Since then, RNTX shares have decreased by 11.2% and is now trading at $1.82.
View the best growth stocks for 2025 here
.

Rein Therapeutics, Inc. (NASDAQ:RNTX) posted its quarterly earnings results on Monday, April, 7th. The company reported ($0.26) earnings per share (EPS) for the quarter.

Shares of RNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/07/2025
Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RNTX
Web
N/A
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-15,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.41 per share
Price / Book
1.29

Miscellaneous

Free Float
20,561,000
Market Cap
$40.03 million
Optionable
N/A
Beta
2.12
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:RNTX) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners